Get the Stockscreener App
10.43
1.55%
-0.22
Rocket Pharmaceuticals Inc stock is traded at $10.43, with a volume of 197.69K.
It is down -1.55% in the last 24 hours and down -16.46% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
See More
Previous Close:
$10.65
Open:
$10.63
24h Volume:
197.69K
Relative Volume:
0.15
Market Cap:
$1.13B
Revenue:
-
Net Income/Loss:
$-258.08M
P/E Ratio:
-3.7927
EPS:
-2.75
Net Cash Flow:
$-202.32M
1W Performance:
-2.38%
1M Performance:
-16.46%
6M Performance:
-44.53%
1Y Performance:
-63.73%
1-Day Range:
$10.45
$10.73
1-Week Range:
$10.11
$11.45
52-Week Range:
$10.07
$31.47
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
10.48 | 1.13B | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.50 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
724.60 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
656.05 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.50 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.19 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Rocket Pharmaceuticals Inc (RCKT) Shares Plummet Below 1-Year High - The News Heater
Jennison Associates LLC Acquires 29,564 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
What was Rocket Pharmaceuticals Inc (RCKT)’s performance in the last session? - US Post News
Holdings of Rocket Pharmaceuticals Inc (RCKT) are aligned with the stars - SETE News
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by SG Americas Securities LLC - MarketBeat
SG Americas Securities LLC Acquires 48,793 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals appoints new board member By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals appoints new board member - Investing.com
Rocket Pharmaceuticals, Inc. Announces Board Changes -January 28, 2025 at 06:03 am EST - Marketscreener.com
Rocket Pharmaceuticals vice president sells $9,300 in stock - MSN
(RCKT) Technical Pivots with Risk Controls - Stock Traders Daily
Rocket Pharmaceuticals vice president sells $9,300 in stock By Investing.com - Investing.com Australia
Leerink Partnrs Has Strong Forecast for RCKT FY2024 Earnings - Defense World
FY2024 Earnings Estimate for RCKT Issued By Leerink Partnrs - MarketBeat
Analysts Offer Predictions for RCKT FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts RCKT FY2025 Earnings - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 52-Week LowHere's What Happened - MarketBeat
Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Price Target at $47.27 - MarketBeat
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Rating of “Moderate Buy” by Analysts - Defense World
RCKT stock touches 52-week low at $10.11 amid market challenges - MSN
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 12-Month Low – Time to Sell? - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 4%Here's Why - MarketBeat
How to Take Advantage of moves in (RCKT) - Stock Traders Daily
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Mirador Capital Partners LP - MarketBeat
JPMorgan Chase & Co. Decreases Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Hits New 12-Month LowHere's What Happened - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 6.9%Time to Buy? - MarketBeat
Learn to Evaluate (RCKT) using the Charts - Stock Traders Daily
RCKTRocket Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Q4 Earnings Estimate for RCKT Issued By Wedbush - Defense World
Brokers Set Expectations for RCKT Q4 Earnings - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading 3.7% HigherWhat's Next? - MarketBeat
Wedbush starts Rocket Pharmaceuticals with Outperform into ‘inflection year’ - Yahoo Finance
Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Analysts at Wedbush - Defense World
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock poised for growth - Investing.com Canada
Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Wedbush - MarketBeat
Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rocket Pharmaceuticals Inc Stock (RCKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Militello John | See Remarks |
Jan 23 '25 |
Sale |
10.38 |
896 |
9,300 |
48,414 |
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):